Tergus Pharma, a topical contract development and manufacturing organization (CDMO), officially opened its new, 100,000 sq. ft. headquarters and commercial manufacturing facility with a ribbon-cutting ceremony on May 13, 2021.
A small company that is all about the development of dermatology drugs has snagged a new investor and will soon start on a manufacturing facility that will catapult it into the CDMO market. Tergus Pharma says an investment from private equity investor Great Point Partners will allow it to build its first commercial manufacturing facility. The Durham, North Carolina-based company currently provides topical formulation development, in vitro permeating testing, clinical trial materials and other services.
Tergus Pharma, LLC, the leading global provider of dermatology Contract Research Organization (CRO) Services, today announced that it has acquired EnDev Laboratories, a Dermatology-centric CRO based in Kannapolis, NC. The acquisition will add extensive early-phase drug development capabilities from lead compound selection to skin biology.